COMPASS Pathways Announces Grant of Inducement Award for Newly Appointed Chief Executive Officer Pursuant to Nasdaq Listing Rule 5635(c)(4)
02 août 2022 16h05 HE
|
COMPASS Pathways
LONDON, Aug. 02, 2022 (GLOBE NEWSWIRE) -- COMPASS Pathways plc (Nasdaq: CMPS) (“COMPASS”), a mental health care company dedicated to accelerating patient access to evidence-based innovation in...
COMPASS Pathways to participate in upcoming BTIG Biotechnology Conference and Canaccord Annual Growth Conference
01 août 2022 08h00 HE
|
COMPASS Pathways
LONDON, Aug. 01, 2022 (GLOBE NEWSWIRE) -- COMPASS Pathways plc (Nasdaq: CMPS), a mental health care company dedicated to accelerating patient access to evidence-based innovation in mental health,...
COMPASS Pathways launches phase II clinical trial of psilocybin therapy in anorexia nervosa
28 juil. 2022 04h00 HE
|
COMPASS Pathways
Multi-centre, double-blind randomised controlled phase II trial will investigate the efficacy of COMP360 psilocybin therapy in anorexia nervosa for which there is currently no approved pharmacological...
COMPASS Pathways plc to announce second quarter 2022 financial results on 4 August 2022
26 juil. 2022 08h00 HE
|
COMPASS Pathways
LONDON, July 26, 2022 (GLOBE NEWSWIRE) -- COMPASS Pathways plc (Nasdaq: CMPS), a mental health care company dedicated to accelerating patient access to evidence-based innovation in mental health,...
COMPASS Pathways appoints Kabir Nath as Chief Executive Officer
19 juil. 2022 08h00 HE
|
COMPASS Pathways
Kabir Nath will build upon COMPASS’ success and lead the development of novel models of care to accelerate patient access to evidence-based innovation in mental health care George Goldsmith remains...
COMPASS Pathways presents largest ever study of psilocybin therapy, at American Psychiatric Association annual meeting
23 mai 2022 07h00 HE
|
COMPASS Pathways
Positive data from phase IIb study shows potential of COMP360 psilocybin therapy in treatment-resistant depression London, UK – 23 May 2022 COMPASS Pathways plc (Nasdaq: CMPS) (“COMPASS”), a...
COMPASS Pathways to participate in upcoming Citi’s Biopharma Virtual Co-Panel Day and H.C. Wainwright Global Investment Conference
12 mai 2022 08h00 HE
|
COMPASS Pathways
LONDON, May 12, 2022 (GLOBE NEWSWIRE) -- COMPASS Pathways plc (Nasdaq: CMPS), a mental health care company dedicated to accelerating patient access to evidence-based innovation in mental health,...
COMPASS Pathways plc announces first quarter 2022 financial results and business highlights
10 mai 2022 07h00 HE
|
COMPASS Pathways
LONDON, May 10, 2022 (GLOBE NEWSWIRE) -- Highlights: End of phase II meeting held with FDAAward of Innovation Passport as part of the UK MHRA Innovative Licensing and Access...
COMPASS Pathways to fund study of COMP360 psilocybin in autistic adults
09 mai 2022 07h00 HE
|
COMPASS Pathways
London, UK – 9 May 2022 COMPASS Pathways plc (Nasdaq: CMPS) (“COMPASS”), a mental health care company dedicated to accelerating patient access to evidence-based innovation in mental health, today...
COMPASS Pathways plc to announce first quarter 2022 financial results on 10 May 2022
03 mai 2022 08h00 HE
|
COMPASS Pathways
LONDON, May 03, 2022 (GLOBE NEWSWIRE) -- COMPASS Pathways plc (Nasdaq: CMPS), a mental health care company dedicated to accelerating patient access to evidence-based innovation in mental health,...